402 related articles for article (PubMed ID: 34798335)
21. Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes.
El Jamaly H; Eslick GD; Weltman M
Clin Mol Hepatol; 2022 Jan; 28(1):52-66. PubMed ID: 34530527
[TBL] [Abstract][Full Text] [Related]
22. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
23. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
24. The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population.
Deng D; George J; Pasupathy D; Wah Cheung N
Diabetes Res Clin Pract; 2021 Apr; 174():108757. PubMed ID: 33744378
[TBL] [Abstract][Full Text] [Related]
25. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
[TBL] [Abstract][Full Text] [Related]
26. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
[TBL] [Abstract][Full Text] [Related]
27. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
[TBL] [Abstract][Full Text] [Related]
28. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
Kim KS; Hong S; Ahn HY; Park CY
Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
[TBL] [Abstract][Full Text] [Related]
29. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
30. Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.
Xie Z; Aimuzi R; Si M; Qu Y; Jiang Y
Front Public Health; 2023; 11():1133194. PubMed ID: 36950101
[TBL] [Abstract][Full Text] [Related]
31. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
[TBL] [Abstract][Full Text] [Related]
32. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
33. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
[TBL] [Abstract][Full Text] [Related]
34. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
[TBL] [Abstract][Full Text] [Related]
35. Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight.
Lee SM; Kim BJ; Koo JN; Norwitz ER; Oh IH; Kim SM; Kim SY; Kim GM; Kwak SH; Kim W; Joo SK; Shin S; Vixa C; Park CW; Jun JK; Park JS
PLoS One; 2019; 14(8):e0221400. PubMed ID: 31449538
[TBL] [Abstract][Full Text] [Related]
36. Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus.
Lee SM; Kwak SH; Koo JN; Oh IH; Kwon JE; Kim BJ; Kim SM; Kim SY; Kim GM; Joo SK; Koo BK; Shin S; Vixay C; Norwitz ER; Park CW; Jun JK; Kim W; Park JS
Diabetologia; 2019 Feb; 62(2):238-248. PubMed ID: 30470912
[TBL] [Abstract][Full Text] [Related]
37. Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD.
Park SH; Park J; Kwon SY; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
Sci Rep; 2023 Jul; 13(1):10677. PubMed ID: 37393407
[TBL] [Abstract][Full Text] [Related]
38. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.
Ng CH; Huang DQ; Nguyen MH
Clin Mol Hepatol; 2022 Oct; 28(4):790-801. PubMed ID: 35545437
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
